Skip to menu Skip to content Skip to footer
Mr Mark Chatfield
Mr

Mark Chatfield

Email: 
Phone: 
+61 7 334 65042

Overview

Background

A/Prof Mark D. Chatfield is a highly experienced statistician in the UQ Clinical Trials Centre and collaborates with researchers across the Faculty of Health, Medicine and Behavioural Sciences.

In collaboration with health and medical researchers, he has published >200 times in academic journals. He has been an investigator on 30 NHMRC/MRFF funded (>$57M) studies (mostly clinical trials). He has >20 years of experience as a biostatistician in Australia (Brisbane, Darwin, Sydney) and the UK (Cambridge, 2002-2009). He has co-supervised 8 PhD students to completion.

He plays an active role in the Australian Clinical Trials Alliance Statistics in Trials Interest Group.

Stata users around the world enjoy using his table1_mc and blandaltman commands.

He is an Honorary Fellow (Associate Professor) with Menzies School of Health Research.

Availability

Mr Mark Chatfield is:
Not available for supervision

Qualifications

  • Bachelor of Arts, University of Oxford
  • Masters (Coursework), University of Southampton
  • Masters (Coursework), University of Oxford

Research interests

  • Clinical trials

    Mark has been involved with a plethora of trials of various designs in a broad range of fields. He makes significant contributions to funding applications, trial design, analysis, presentation and interpretation. To date, he has published on 39 randomised trials (protocol and/or results paper). He is involved with methodological research into cluster randomised trials as well as sample size calculations.

  • Meta-analysis

    Mark has been involved with a variety of meta-analyses. He has found a novel way to interpret the heterogeneity parameter, tau, in random-effects meta-analysis of ratios. That said, he advocates for the reporting of tau, or exp(tau) for ratios, rather than tau^2 as it is most easily understood.

Works

Search Professor Mark Chatfield’s works on UQ eSpace

304 works between 2004 and 2026

261 - 280 of 304 works

2012

Journal Article

Electroacupuncture for nausea, vomiting, and myelosuppression in women receiving adjuvant chemotherapy for early breast cancer: a randomized controlled pilot trial

Beith, Jane M., Oh, Byeongsang, Chatfield, Mark D., Davis, Esther and Venkateswaran, Ramya (2012). Electroacupuncture for nausea, vomiting, and myelosuppression in women receiving adjuvant chemotherapy for early breast cancer: a randomized controlled pilot trial. Medical Acupuncture, 24 (4), 241-248. doi: 10.1089/acu.2012.0876

Electroacupuncture for nausea, vomiting, and myelosuppression in women receiving adjuvant chemotherapy for early breast cancer: a randomized controlled pilot trial

2012

Journal Article

Dietary iron is associated with memory in midlife: longitudinal cohort study

Rickard, Anna P., Chatfield, Mark D., Powell, Jonathan J., Stephen, Alison M. and Richards, Marcus (2012). Dietary iron is associated with memory in midlife: longitudinal cohort study. Journal of Pharmacy and Nutrition Sciences, 2 (1), 57-62. doi: 10.6000/1927-5951.2012.02.01.8

Dietary iron is associated with memory in midlife: longitudinal cohort study

2012

Journal Article

Definitive radiotherapy or chemoradiotherapy in the treatment of Merkel cell carcinoma

Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M. and Thompson, J. F. (2012). Definitive radiotherapy or chemoradiotherapy in the treatment of Merkel cell carcinoma. Clinical Oncology, 24 (9), E131-E136. doi: 10.1016/j.clon.2012.04.007

Definitive radiotherapy or chemoradiotherapy in the treatment of Merkel cell carcinoma

2012

Journal Article

Antibiotics for bronchiectasis exacerbations in children: Rationale and study protocol for a randomised placebo-controlled trial

Chang, Anne B., Grimwood, Keith, Robertson, Colin F., Wilson, Andrew C., van Asperen, Peter P., O'Grady, Kerry-Ann F., Sloots, Theo P., Torzillo, Paul J., Bailey, Emily J., Mccallum, Gabrielle B., Masters, Ian B., Byrnes, Catherine .A, Buntain, Helen M., Morris, Peter S., Mackay, Ian M. and Chatfield, Mark D. (2012). Antibiotics for bronchiectasis exacerbations in children: Rationale and study protocol for a randomised placebo-controlled trial. Trials, 13 (156) 156, 156-1-156-9. doi: 10.1186/1745-6215-13-156

Antibiotics for bronchiectasis exacerbations in children: Rationale and study protocol for a randomised placebo-controlled trial

2012

Journal Article

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy

Savdie, Richard, Horvath, Lisa G., Benito, Ruth Pe, Rasiah, Krishan K., Haynes, Anne-Maree, Chatfield, Mark, Stricker, Phillip D., Turner, Jennifer J., Delprado, Warwick, Henshall, Susan M., Sutherland, Robert L. and Kench, James G. (2012). High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy. BJU International, 109 (12), 1794-1800. doi: 10.1111/j.1464-410X.2011.10572.x

High Gleason grade carcinoma at a positive surgical margin predicts biochemical failure after radical prostatectomy and may guide adjuvant radiotherapy

2012

Conference Publication

Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC)

Sjoquist, Katrin Marie, Lee, Chee, Lord, Sally, Chatfield, Mark D., Friedlander, Michael, Simes, John and Marschner, Ian (2012). Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC)

2012

Conference Publication

EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901)

Davis, Ian D., Gebski, Val, Chatfield, Mark D., Grimison, Peter S., Kannourakis, George, Boland, Amy L., Thompson, Jennifer and Stockler, Martin R. (2012). EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901). 48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 01-06, 2012. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (RCC) (ANZUP trial 0901)

2012

Journal Article

HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre

Whalley, Deborah, Patanjali, Nitya, Jackson, Michael, Lovett, Aimee, Chatfield, Mark and Hruby, George (2012). HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre. Journal of Medical Imaging and Radiation Oncology, 56 (2), 220-226. doi: 10.1111/j.1754-9485.2012.02358.x

HDR brachytherapy combined with external beam radiation for localised prostate cancer: early experience from the Sydney Cancer Centre

2012

Conference Publication

Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials

Grimison, Peter S., Chatfield, Mark D., Mazhar, Danish, Toner, Guy C., Chester, John D., Stockler, Martin R., Stark, Daniel P., Thomson, Damien B., Shamash, Jonathan, Friedlander, Michael, White, Jeff, Gebski, Val, Wason, James, Boland, Amy L., Rimmer, Yvonne L., McDonald, Angus, Gurney, Howard, Rosenthal, Mark, Singhal, Nimit and Williams, Michael V. (2012). Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials. 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), Chicago, Il United States, 01-06 June 2012. Alexandria, VA United States: American Society of Clinical Oncology.

Accelerated BEP for metastatic germ cell tumors: Combined analysis of Australian and UK phase I/II trials

2011

Journal Article

Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy

Kao, Steven Chuan-Hao, Klebe, Sonja, Henderson, Douglas W., Reid, Glen, Chatfield, Mark, Armstrong, Nicola J., Yan, Tristan D., Vardy, Janette, Clarke, Stephen, van Zandwijk, Nico and McCaughan, Brian (2011). Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy. Journal of Thoracic Oncology, 6 (11), 1923-1929. doi: 10.1097/JTO.0b013e31822a3740

Low Calretinin Expression and High Neutrophil-To-Lymphocyte Ratio Are Poor Prognostic Factors in Patients with Malignant Mesothelioma Undergoing Extrapleural Pneumonectomy

2011

Conference Publication

Factors Affecting Time From Surgery to Adjuvant Chemotherapy for Early Breast Cancer in a Rural and Urban Medical Oncology Unit - a Retrospective Cohort Study

Fox, P. N., Chatfield, M. D., Beith, J., Turley, K. and Grimison, P. S. (2011). Factors Affecting Time From Surgery to Adjuvant Chemotherapy for Early Breast Cancer in a Rural and Urban Medical Oncology Unit - a Retrospective Cohort Study. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm Sweden, Sep 23-27, 2011. OXFORD: ELSEVIER SCI LTD. doi: 10.1016/S0959-8049(11)71216-3

Factors Affecting Time From Surgery to Adjuvant Chemotherapy for Early Breast Cancer in a Rural and Urban Medical Oncology Unit - a Retrospective Cohort Study

2011

Conference Publication

Patterns of Care for Stage 1 Testicular Cancer in Australia in 2010

Houghton, B., Stockler, M., Chatfield, M. D., Toner, G., Davis, I. D. and Grimison, P. S. (2011). Patterns of Care for Stage 1 Testicular Cancer in Australia in 2010. European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care, Stockholm Sweden, Sep 23-27, 2011. OXFORD: ELSEVIER SCI LTD.

Patterns of Care for Stage 1 Testicular Cancer in Australia in 2010

2011

Conference Publication

PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN A COHORT OF PATIENTS COMPENSATED BY THE DUST DISEASES BOARD

Kao, Steven C., Clarke, Stephen, Chatfield, Mark, Corte, Peter, Clarke, Christopher, Vardy, Janette and Van Zandwijk, Nico (2011). PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN A COHORT OF PATIENTS COMPENSATED BY THE DUST DISEASES BOARD. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

PROGNOSTIC FACTORS IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) IN A COHORT OF PATIENTS COMPENSATED BY THE DUST DISEASES BOARD

2011

Conference Publication

CALRETININ EXPRESSION IMPROVES THE PREDICTIVE ACCURACY IN SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) UNDERGOING EXTRAPLEURAL PNEUMONECTOMY (EPP)

Kao, Steven C., Klebe, Sonja, Henderson, Douglas W., Reid, Glen, Chatfield, Mark, Armstrong, Nicola, Yan, Tristan, Vardy, Janette, Clarke, Stephen, Van Zandwijk, Nico and Mccaughan, Brian (2011). CALRETININ EXPRESSION IMPROVES THE PREDICTIVE ACCURACY IN SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) UNDERGOING EXTRAPLEURAL PNEUMONECTOMY (EPP). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

CALRETININ EXPRESSION IMPROVES THE PREDICTIVE ACCURACY IN SURVIVAL IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) UNDERGOING EXTRAPLEURAL PNEUMONECTOMY (EPP)

2011

Conference Publication

MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)

Yip, Po Yee, Cooper, Wendy, Mahar, Annabelle, Kench, James, Kohonen-Corish, Maija R. J., Chatfield, Mark, Boulghourjian, Alice, Kennedy, Catherine W., Mccaughan, Brian, Boyer, Michael and Horvath, Lisa (2011). MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

MARKERS OF PROGNOSIS IN RESECTED STAGE IB NON-SMALL CELL LUNG CANCER (NSCLC)

2011

Conference Publication

Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial

Grimison, P. S., Thomson, D. B., Stockler, M. R., Chatfield, M. D., Friedlander, M., Gebski, V., Boland, A. L., Houghton, B. B., Gurney, H., Rosenthal, M., Singhal, N., Kichenadasse, G., Wong, S. S., Lewis, C. R., Vasey, P. A. and Toner, G. C. (2011). Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.4561

Accelerated BEP for advanced germ cell tumors: An Australian multicenter phase I/II trial

2011

Conference Publication

Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi)

Long, G. V., Wilmott, J. S., Howle, J. R., Chatfield, M. D., Tembe, V., Thompson, J. F., Hersey, P., Mann, G. J., McArthur, G. A., Rizos, H., Young, R. J., Scurr, L. L., Sharma, R. N., Kefford, R. F. and Scolyer, R. A. (2011). Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.8542

Morphologic and immunohistochemical (IHC) changes in metastatic melanoma (MM) tissue and associations with clinical outcome in patients (pts) on BRAF inhibitors (BRAFi)

2011

Conference Publication

BRAF mutation by age-decade and body mass index in metastatic melanoma

Menzies, A. M., Visintin, L., Chatfield, M. D., Carlino, M. S., Howle, J. R., Scolyer, R. A., Thompson, J. F., Kefford, R. F. and Long, G. V. (2011). BRAF mutation by age-decade and body mass index in metastatic melanoma. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY.

BRAF mutation by age-decade and body mass index in metastatic melanoma

2011

Conference Publication

Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC)

Mahon, K. L., Chatfield, M. D., Lee-Ng, M., Breit, S. N., Brown, D. A., Molloy, M. P., Marx, G. M., Pavlakis, N., Boyer, M. J., Stockler, M. R., Wykes, R., Henshall, S. M., Sutherland, R. L. and Horvath, L. (2011). Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.4598

Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC)

2011

Conference Publication

A study of <i>methylated glutathione s-transferase 1 (mGSTP1)</i> as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC)

Horvath, L., Mahon, K. L., Qu, W., Devaney, J., Chatfield, M. D., Paul, C., Wykes, R., Boyer, M. J., Stockler, M. R., Marx, G. M., Sutherland, R. L. and Clark, S. J. (2011). A study of methylated glutathione s-transferase 1 (mGSTP1) as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. doi: 10.1200/jco.2011.29.15_suppl.4603

A study of <i>methylated glutathione s-transferase 1 (mGSTP1)</i> as a potential plasma epigenetic marker of response to chemotherapy and prognosis in men with castration-resistant prostate cancer (CRPC)

Funding

Current funding

  • 2026 - 2028
    Matching multidisciplinary management strategies to people with chronic musculoskeletal pain: the MATCH pilot and feasibility randomised clinical trial
    NHMRC MRFF Novel treatments and management strategies for chronic pain
    Open grant
  • 2026 - 2028
    Vibrotexture Insole Technology for Balance Rehabilitation in People with Multiple Sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2025 - 2028
    Improving Food Allergy Outcomes in Adolescents
    NHMRC Clinical Trials and Cohort Studies Grants
    Open grant
  • 2024 - 2028
    The clinical and cost effectiveness of the Action Falls rehabilitation programme compared to usual care alone to reduce falls in stroke survivors (The FISS-AUSTRALIA trial)
    NHMRC-National Institute for Health Research (NIHR) Collaborative Research Grants
    Open grant
  • 2024 - 2027
    Losing touch: Exploring the neurophysiological effects of bionic sensory insole technology for balance rehabilitation
    NHMRC IDEAS Grants
    Open grant
  • 2024 - 2027
    Co-creating virtual environments with consumers to enhance self-awareness and preparedness for home after brain injury
    NHMRC MRFF PPHR - Consumer Led Research
    Open grant
  • 2023 - 2028
    The clinical and cost-effectiveness of lumbar fusion surgery for patients with persistent, severe low back pain: FusiOn veRsus bEst coNServative Care (the FORENSIC trial)
    NHMRC-National Institute for Health Research (NIHR) Collaborative Research Grants
    Open grant
  • 2023 - 2028
    Enhancing utility of neuropsychological evaluation for earlier and effective diagnosis of dementia in Parkinson's disease
    NHMRC MRFF Dementia, Ageing and Aged Care Mission
    Open grant
  • 2023 - 2027
    Pharmacogenomics for better treatment of fungal infections in cancer
    MRFF Quality, Safety and Effectiveness of Medicine Use and Medicine Intervention by Pharmacists
    Open grant
  • 2022 - 2028
    ACTIVE KNEECAPs! tArgeted effeCTIVE treatments for adolescent KNEECAP pain
    NHMRC MRFF EPCDR - Chronic Musculoskeletal Conditions in Children and Adolescents
    Open grant
  • 2022 - 2028
    Optimising Care: Phase III Trial in women with metastatic breast cancer to improve quality of life via exercise and diet (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2026
    Technology Assisted and Remotely Delivered Anxiety Psychotherapy Intervention for People living with Dementia and Their Care Partners (Tech-CBT)
    NHMRC MRFF Dementia, Ageing and Aged Care Mission
    Open grant
  • 2019 - 2026
    Preventing recurrent respiratory-related hospitalisations in young Indigenous children through regular azithromycin: a multi-centre.... (NHMRC Project Grant led by Menzies School of Health Research)
    Menzies School of Health Research
    Open grant

Past funding

  • 2019 - 2024
    Improving outcomes of children and young adults with primary ciliary dyskinesia (PCD):... (MRFF RCRDUN administered by Menzies School of Health Research)
    Menzies School of Health Research
    Open grant
  • 2019
    Cluster randomised trial of Staphylococcus aureus decolonisation to prevent surgical site infections
    HCF Research Foundation
    Open grant

Supervision

Availability

Mr Mark Chatfield is:
Not available for supervision

Supervision history

Current supervision

  • Doctor Philosophy

    Novel trial design in evaluation of antibiotics.

    Associate Advisor

    Other advisors: Dr Patrick Harris

Completed supervision

Media

Enquiries

For media enquiries about Mr Mark Chatfield's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au